Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 401–500 of 769
Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Li, Q., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 8
Leng, L., Liao, Z., Lu, P., Sun, Y., Weng, Q., Fan, W., Zhu, H., Wu, W., Liu, P., Liu, X., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251406619 · Cited by 8
Zhang, L., Du, X., Zhang, T., Chen, Q., Zhang, Q., Su, Y., Zhang, M., & Luo, H. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.139417 · Cited by 8
Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
Kim, H., Lee, J. H., Chun, J., Kim, Y. J., Park, M., West, T., Kirmess, K. M., Verghese, P. B., Connell, D., Braunstein, J. B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71199 · Cited by 8
Lu, S., Qiu, S., Yu, G., Zhang, A., & Zhao, Q. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103097 · Cited by 8
Singh, K., Cheung, B. M. Y., & Xu, A. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0219 · Cited by 8
Palomo, M. S. M., & Zea‐Sevilla, M. A. (2023) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2023.03.002 · Cited by 8
Toward Prevention and Reduction of Alzheimer’s Disease
González-Madrid, A., Calfío, C., González, A., Lüttges, V., & Maccioni, R. B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230454 · Cited by 8
de Ávila, C., Suazo, C., Nolz, J., Cochran, J. N., Wang, Q., Velázquez, R., Dammer, E. B., Readhead, B., & Mastroeni, D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.06.007 · Cited by 8
Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer's disease
Zhuang, T., Yang, Y., Ren, H., Zhang, H., Gao, C. Q., Chen, S., Shen, J., Ji, M., & Cui, Y. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105650 · Cited by 8
Diagnosing Alzheimer’s Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe
Black, S. A. G., Stepanchuk, A. A., Templeton, G. W., Hernandez, Y., Ota, T., Roychoudhury, S., Smith, E. E., Barber, P. A., Ismail, Z., Fischer, K., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215402 · Cited by 8
Self-citationBiomarqueurs de la maladie d’Alzheimer : des avancées très rapides
Vrillon, A., & Paquet, C. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.01.013 · Cited by 8
A Blood Test for Alzheimer’s Disease: It’s about Time or Not Ready for Prime Time?
Galasko, D. R., Grill, J. D., Lingler, J. H., & Heidebrink, J. L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215490 · Cited by 8
Blood Biomarkers Predict Future Cognitive Decline after Military-Related Traumatic Brain Injury
Lippa, S. M., Gill, J., Brickell, T. A., Guedes, V. A., French, L. M., & Lange, R. T. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220330144432 · Cited by 8
Islam, T., Kvartsberg, H., Sehrawat, A., Kac, P. R., Becker, B., Olsson, M., Abrahamson, E. E., Zetterberg, H., Ikonomović, M. D., Blennow, K., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13711 · Cited by 8
Self-citationCheng, Y., Lin, Y., Lin, Y., Hong, W., Kuan, Y., Wu, K.-Y., Hsu, J., Wang, P., Pai, M., Chen, C., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.01.018 · Cited by 8
Preclinical and Prodromal Frontotemporal Dementia: Challenges and Opportunities
Palacino, F., Manganotti, P., & Benussi, A. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040052 · Cited by 7
Abboud, I., Xu, E. M., Xu, S., Alhasany, A., Wang, Z. C., Wu, X., Astraea, N., Jiang, F., Hu, Z. J., & Chan, J. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010275 · Cited by 7
Yang, S. J., Lin, A. A., Shen, H., Pappalardo, L. W., Spychalski, G. B., Rosario, J. G., Forsberg, L. K., Grant, K. M., Buser, J. R., Savica, R., et al. (2026) · npj Biosensing · doi:10.1038/s44328-026-00086-x · Cited by 7
Gaetani, L., Agnello, L., Pilotto, A., Benussi, A., Cagnin, A. C., Parnetti, L., Bozzali, M., Padovani, A., Ciaccio, M., the Italian Society of Neurology (SIN) Study Group on Biomarkers in Neurology, et al. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08931-7 · Cited by 7
Amabebe, E., Huang, Z., Jash, S., Krishnan, B., Cheng, S., Nakashima, A., Li, Y., Li, Z., Wang, R., Menon, R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines13010029 · Cited by 7
Plasma phosphorylated tau and neuropsychiatric symptoms in dementia with Lewy bodies
Gibson, L. L., González, M. C., Ashton, N. J., Tovar, D., Blanc, F., Pilotto, A., Lemstra, A. W., Paquet, C., Ballard, C. G., Zetterberg, H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14434 · Cited by 7
Self-citationAlpaugh, M., Lantero‐Rodriguez, J., Benedet, A. L., Manseau, U., Boutin, M., Maiuri, M., Denis, H. L., Masnata, M., Fazal, S. V., Chouinard, S., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12966-9 · Cited by 7
Self-citationSun, S., Chen, S., He, J., Yang, B., Zhang, Y., Li, N., Wang, H., Tam, K. Y., & Ying, Z. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118290 · Cited by 7
Xu, C., Zhao, L., & Dong, C. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16085 · Cited by 7
Álvarez‐Sánchez, L., Ferré‐González, L., Peña‐Bautista, C., Balaguer, Á., Amengual, J. L., Baquero, M., Cubas-Núñez, L., Casanova, B., & Cháfer‐Pericás, C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70034 · Cited by 7
Kinase inhibition in Alzheimer’s disease
Bagheri, S., & Saboury, A. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00003-x · Cited by 7
Groot, C., Cicognola, C., Bali, D., Triana‐Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Ossenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01023-6 · Cited by 7
Wu, L., Su, J., Li, G., Zhuang, M., Sun, H., & Zhang, J. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf058 · Cited by 6
Ying, C., & Lin, F. (2025) · NeuroImmunoModulation · doi:10.1159/000548491 · Cited by 6
Bolton, C. J., Khan, O. A., Liu, D., Pechman, K. R., Gifford, K. A., Hohman, T. J., Blennow, K., Zetterberg, H., & Jefferson, A. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70796 · Cited by 6
Self-citationKim, K. Y., Shin, K. Y., & Chang, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110330 · Cited by 6
Schmidt, V., Ziemlińska, E., Obrębski, T., Gomes, J. P., Żurawska-Płaksej, E., Cendrowski, J., Palmfeldt, J., Hempstead, B. L., Willnow, T. E., & Malik, A. R. (2025) · Nature Communications · doi:10.1038/s41467-025-65536-y · Cited by 6
Russotto, A., Longobardi, A., Ciullini, A., Cazzaniga, F. A., Bacınoğlu, M. B., Borroni, B., Ghidoni, R., Moda, F., & Saraceno, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07471-6 · Cited by 6
Recent advances in single-molecule immunoassays and their clinical applications
Li, B., Liu, Y., Kong, L., Yin, K., Zhang, P., & Wang, X. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118604 · Cited by 6
Brodman, S. T., Heaton, N., Triana‐Baltzer, G., Zeng, X., Gogola, A., Kamboh, M. I., Villemagne, V. L., López, O. L., Kolb, H. C., Deek, R. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70985 · Cited by 6
Self-citationShabana, S., Hamouda, H. I., Shang, A., Shao, S., Zhao, J., Yuan, H., & Liu, B. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01932-2 · Cited by 6
Abbasi, A. A., Jokhio, F., Norouziyan, F., & Moradikor, N. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100150 · Cited by 6
Karur, P., Kaldas, M., Babu, Y. S. R., & Parmar, M. S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05647-1 · Cited by 6
Dallaire‐Théroux, C., Denis, H. L., Cottez, R. J., Tremblay, C., Provencher, A., Valentin‐Escalera, J., Leclerc, M., Loiselle, A., Tournissac, M., Potvin, O., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71097 · Cited by 6
Self-citationDeek, R. A., Balogun, W. G., Zeng, X., Triana‐Baltzer, G., Pascoal, T. A., Kolb, H. C., Snitz, B. E., Cohen, A. D., & Karikari, T. K. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01969-x · Cited by 6
Self-citationNanozymes Based Biosensors for Detection of Biomarkers in Brain Diseases
Teng, L., Tan, H., Bai, W., Yu, X., Li, Q., Wang, C., Zhang, H., Li, S., Yao, Y., Zhuang, W., et al. (2026) · Small · doi:10.1002/smll.202510732 · Cited by 6
Blood proteomics of menopause map to brain aging and dementia risk
Alexander, M. W., Rabin, J. S., Caunca, M. R., Iadipaolo, A. S., Cornelis, L., Warrier, R., Walker, K. A., Miolane, N., Bot, V. A., Wood, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04648-4 · Cited by 6
Self-citationLu, X., Zhou, Y., Miao, Q.-S., Han, X., Zhou, Y. K., Zhao, G., Yu, H., & Chen, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1392813 · Cited by 6
Minimum spanning tree analysis of unimpaired individuals at risk of Alzheimer’s disease
García‐Colomo, A., López‐Sanz, D., Stam, C. J., Hillebrand, A., Carrasco-Gómez, M., Spuch, C., Comís‐Tuche, M., & Maestú, F. (2024) · Brain Communications · doi:10.1093/braincomms/fcae283 · Cited by 6
Use of biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability
McFeely, A., O’Connor, A., & Kennelly, S. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.100639 · Cited by 6
Lewis, J. M., Harris, D.-A., Kosmatka, J., Mikrut, E., Evenson, J., Balcer, H. I., Dhani, H., Hinestrosa, J. P., Rissman, R. A., & Billings, P. R. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241291964 · Cited by 6
Novel insights into Cntnap4 in Alzheimer's disease: Intestinal flora interaction
Xiao, X., Guan, Y., Mo, H., Lv, K., Chen, J., Xie, J., Meng, Q., Liu, J., Lu, Y., Gao, F., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138508 · Cited by 6
Blood biomarkers as surrogate endpoints in Alzheimer’s disease research
Shan, G., Li, H., Zhang, Y., Wang, G., & Bernick, C. B. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1576373 · Cited by 6
Lee, D., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00719-3 · Cited by 6
How reproducible are data-driven subtypes of Alzheimer's disease atrophy?
Prevot, E., Shand, C., Initiative, A. D. N., & Oxtoby, N. P. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251415019 · Cited by 5
Zinkunegi, A. J., Wilson, R. E., Langhough, R. E., Ashton, N. J., Blennow, K., Johnson, S. C., Zetterberg, H., Bruno, D., & Mueller, K. D. (2025) · The Clinical Neuropsychologist · doi:10.1080/13854046.2025.2481119 · Cited by 5
Self-citationTau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology
Bezgin, G., Pascoal, T. A., Therriault, J., Lussier, F. Z., Servaes, S., Kang, M. S., Savard, M., Tissot, C., Stevenson, J., Wang, Y.-T., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07257-4 · Cited by 5
Self-citationFu, S.-Y., Zheng, Q., Xu, B., & Chen, F. (2025) · View · doi:10.1002/viw.20240119 · Cited by 5
Plasma Proteomic Analysis for Alzheimer’s Disease Biomarkers, Pathways, and Subgroup Identification
Peña‐Bautista, C., Álvarez‐Sánchez, L., Balaguer, Á., Ferré‐González, L., Peretó, M., Baquero, M., & Cháfer‐Pericás, C. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00513 · Cited by 5
Addressing global diversity in dementia research with the COSMIC collaboration
Lipnicki, D. M., Vella, A. S., Jiang, J., Mewton, L. R., Matison, A. P., Mather, K. A., Thalamuthu, A., Catts, V. S., Chen, R., Husein, N. K., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.036 · Cited by 5
Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions
Zheng, M., Wang, S., & Jia, J. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554515 · Cited by 5
Ji, Q., Lian, W., Liu, W., Tang, L., Hu, Z., Li, L., Wang, Y., Tao, E., & Zhan, Y. (2025) · Neuroepidemiology · doi:10.1159/000548365 · Cited by 5
Zhao, X., & He, Z. (2025) · Neuroscience Research · doi:10.1016/j.neures.2025.104979 · Cited by 5
Patsyuk, Y., Egroo, M. V., Beckers, E., Koops, E. A., Ashton, N. J., Janelidze, S., Blennow, K., Hansson, O., Zetterberg, H., Poser, B. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70915 · Cited by 5
Self-citationDulewicz, M., Kac, P. R., Ortiz, F. G., Karikari, T. K., Kulczyńska‐Przybik, A., Mroczko, B., Turton, M., Harrison, P., Maler, M., Oberstein, T. J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70313 · Cited by 5
Self-citationPlasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology
Kac, P. R., González‐Escalante, A., Milà‐Alomà, M., Ashton, N. J., Shekari, M., Ortiz‐Romero, P., Turton, M., Harrison, P., Zetterberg, H., Gispert, J. D., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13572-5 · Cited by 5
Self-citationAdvances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 5
Patil, V., Sharma, A., Parekh, B. K., Jyothi.S, R., Priyadarshini‐Nayak, P., Janney-J, B., Singh, G., Al-Hasnaawei, S., & Kumar-Mishra, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05634-6 · Cited by 5
Status of Alzheimer’s and Parkinson’s Disease Detections and Treatments
Nguyen, P. H., & Derreumaux, P. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00096 · Cited by 5
Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview
Manzine, P. R., Vatanabe, I. P., Grigoli, M. M., Pedroso, R. V., Monteiro, M. P. A. O., de Oliveira, D. D. S. M. S., Nascimento, C. M. C., Peron, R., Orlandi, F. D. S., & Cominetti, M. R. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220408124809 · Cited by 5
Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease
Yakoub, Y., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Montoliu‐Gaya, L., Meyer, P., St‐Onge, F., Schöll, M., Breitner, J. C. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.064811 · Cited by 5
Self-citationRecent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 5
Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects
Martínez‐Dubarbie, F., López‐García, S., Lage, C., Molfetta, G. D., Fernández‐Matarrubia, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., Jiménez-Bonilla, J. F., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231479 · Cited by 5
Self-citationÞorgeirsdóttir, B., Sievert, T., Lybeck, A., Ashton, N. J., Blennow, K., Zetterberg, H., Friberg, H., & Frigyesi, A. (2024) · Resuscitation · doi:10.1016/j.resuscitation.2024.110450 · Cited by 5
Self-citationEmmerson, J. T., Carmo, S. D., Lavagna, A., Huang, C., Wong, T. P., Martínez-Trujillo, J., & Cuello, A. C. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01901-0 · Cited by 5
Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
Hsiao, W. W., Angela, S., Le, T., Ku, C., Hu, P., & Chiang, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221202 · Cited by 5
Park, M., Ahn, J., Lim, J., Hwang, S., & Kim, K. (2025) · GeroScience · doi:10.1007/s11357-025-01869-2 · Cited by 4
Athanasaki, A., Tsantzali, I., Theodorou, A., Michalopoulou, A., Constantinides, V. C., Boufidou, F., Tzartos, J. S., Tsalouchidou, P., Zompola, C., Paraskevas, S. G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199531 · Cited by 4
Genetic and environmental contributions to variation in plasma phosphorylated tau 217
Rousset, R. Z., Dolan, C. V., Wilson, D. H., Veld, L. I. ‘., Ligthart, L., Teunissen, C. E., de Geus, E. J. C., & den Braber, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70906 · Cited by 4
Mattsson, N., Karlsson, L., Tang, W., Blennow, K., Zetterberg, H., Bateman, R. J., Schindler, S. E., Barthélemy, N. R., Palmqvist, S., Stomrud, E., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00348-7 · Cited by 4
Self-citationPlasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy
Lee, S., Kim, H., Kim, R., Jin, B., Kim, S., Ha, S. H., Shin, J. H., Jeon, B., Kim, H.-J., & Lee, J.-Y. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13570-7 · Cited by 4
Signaling Molecules and Diagnosis of Cognitive Disorders: Current State and Prospects
Kvetnoy, I. M., Kheyfets, O., Safaniev, L., Kheifets, V., Mironova, E. S., Kvetnaia, T. V., Mazzoccoli, G., Prashchayeu, K. I., & Gavrilova, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010372 · Cited by 4
Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries
Halbgebauer, R., González‐Ortiz, F., Mayer, B., Berger, C., Bergmann, C. B., Rinderknecht, H., Barth, E., Wohlgemuth, L., Mannes, M., Otto, M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.58573 · Cited by 4
Self-citationCánovas, R., Fowler, C. J., Feizpour, A., Doré, V., Bourgeat, P., Saad, Z. S., Triana‐Baltzer, G., Kolb, H. C., Vandijck, M. L. J., Kollmorgen, G., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71145 · Cited by 4
Self-citationPost-translational modifications as a regulatory code for tau function in health and disease
Nordbeck, A. J., Sharma, B., Garcia, C. A., & Tseng, J. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1834737 · Cited by 4
Bastgen, T., Evers, J., Oedekoven, C., Weide, C., Herzog, L., Ashton, N. J., Zetterberg, H., Blennow, K., Albus, A., Vidovic, N., et al. (2024) · Neurological Research and Practice · doi:10.1186/s42466-024-00307-6 · Cited by 4
Self-citationEffects of Alzheimer’s disease plasma marker levels on multilayer centrality in healthy individuals
García‐Colomo, A., López‐Sanz, D., Taguas, I., Carrasco-Gómez, M., Spuch, C., Comís‐Tuche, M., & Maestú, F. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01654-x · Cited by 4
Zhao, Y., Wang, X., Zhang, J., Zhao, Y., Li, Y., Shen, J., Yuan, Y., & Li, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1663276 · Cited by 4
Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer’s disease
QUAN, X., MA, X., LI, G., FU, X., LI, J., & ZENG, L. (2023) · Biocell · doi:10.32604/biocell.2023.031226 · Cited by 4
Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ?
Delaby, C., & Lehmann, S. (2024) · médecine/sciences · doi:10.1051/medsci/2024037 · Cited by 4
Zhang, D., Chen, K., & Shan, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14683 · Cited by 4
Glucose starvation induces tau phosphorylation leading to cellular stress response in fission yeast
Yılmazer, M., Şengelen, A., Aksüt, Y., Palabıyık, B., Uçar, E. Ö., & Uzuner, S. K. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04350-y · Cited by 4
García‐Colomo, A., López‐Sanz, D., Carrasco-Gómez, M., Ramírez‐Toraño, F., Alfonsín, S., Spuch, C., Comís‐Tuche, M., & Maestú, F. (2025) · GeroScience · doi:10.1007/s11357-025-01743-1 · Cited by 4
Strategies for translating proteomics discoveries into drug discovery for dementia
Halder, A., & Drummond, E. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373681 · Cited by 4
Central and peripheral tau retention modulated by an anti-tau antibodyPreprint
Solorzano, A. G., Brady, M., Bhatt, N. N., Johnson, A., Burgess, B., Leyva, H., Puangmalai, N., Jerez, C., Wood, R. W., Kayed, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.17.553682 · Cited by 5
The Alzheimer disease continuum : findings from monogenic Alzheimer disease
Johansson, C. (2025) · doi:10.69622/28639856 · Cited by 4
Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications
Jamerlan, A., An, S. S. A., & Hulme, J. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123325 · Cited by 3
Idris, M., Saini, F., Ivain, P., Baksh, R. A., Bianchi, L. A., Pape, S. E., Zetterberg, H., Wijeratne, P. A., & Strydom, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70446 · Cited by 3
Self-citationde Lucia, C., Tovar, D., Khalifa, K. N., Kvernberg, S. M., Pola, I., Bergland, A. K., Maple‐Grødem, J., Siow, R. C. M., Ashton, N. J., Ballard, C. G., et al. (2025) · Nutrients · doi:10.3390/nu17162680 · Cited by 3
Self-citationLabel-free plasmonic biosensors for neurodegenerative disease diagnosis: Progress and perspectives
Dun, Y., Chang, L., Zhang, S., Wang, Y., He, X., Zhang, G., & Zhou, J. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118488 · Cited by 3
Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathy
Aumont, É., Amiel, K., Lopez, D. O., Arias, J. F., Montembeault, M., Bezgin, G., Hall, B. J., Trudel, L., Chan, T., Rahmouni, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-21260-7 · Cited by 3
Self-citationDiffusion Alterations at the Gray Matter/White Matter Boundary in Traumatic Encephalopathy Syndrome
Wiegand, T. L. T., Pankatz, L., Arciniega, H., Jung, L., Tuz‐Zahra, F., Bouix, S., Lubeck, H., Rojczyk, P., Schuhmacher, L. S., Buring, J. E., et al. (2025) · Journal of Neurotrauma · doi:10.1177/08977151251393966 · Cited by 3
Self-citationCai, Y., Snitz, B. E., & Cohen, A. D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71181 · Cited by 3
Vigneswaran, S., Verberk, I. M. W., Rousset, R. Z., Gouda, M., Trieu, C., Claessen, T., van de Giessen, E., Lemstra, A. W., Wilson, D. J., Pijnenburg, Y. A. L., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01979-9 · Cited by 3
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.